Neurogene (NGNE) Share-based Compensation (2013 - 2026)

Neurogene has reported Share-based Compensation for 14 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 10.35% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (up 21.56% YoY), and the FY2025 full-year result was $14.2 million, up 70.47% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.6 million, up from $3.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.0 million in Q1 2025, with the low at -$5.5 million in Q4 2022.
• Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 284.01% — and 2024, when it surged 600.56%.
• Neurogene's Share-based Compensation stood at -$5.5 million in 2022, then surged by 106.41% to $355000.0 in 2023, then surged by 600.56% to $2.5 million in 2024, then soared by 35.18% to $3.4 million in 2025, then advanced by 7.94% to $3.6 million in 2026.
• The last three Share-based Compensation figures came in at $3.6 million (Q1 2026), $3.4 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.